Lonza shareholders back board slate and raise dividend at 2026 AGM

Lonza Group Ltd ( (CH:LONN) ) just unveiled an announcement.

Lonza’s 2026 Annual General Meeting saw shareholders approve all proposals from the Board, underscoring strong investor support for the company’s governance and strategy. Jean-Marc Huët was re-elected as Chairman, all incumbent directors standing for re-election retained their seats, and three new board members – Claudia Süssmuth-Dyckerhoff, Sami Atiya and Stephen Fry – were appointed, while the Nomination and Compensation Committee was refreshed and Deloitte reappointed as statutory auditor for 2027.

Shareholders backed the company’s compensation proposals and non-financial report and approved a dividend of CHF 5.00 per share, a 25% increase on the prior year, with half to be paid from the capital contribution reserve and exempt from Swiss withholding tax. The higher payout reflects confidence in Lonza’s financial performance and outlook, offering a tangible benefit to investors and reinforcing the group’s positioning as a key CDMO player in global healthcare markets.

The most recent analyst rating on (CH:LONN) stock is a Buy with a CHF670.00 price target. To see the full list of analyst forecasts on Lonza Group Ltd stock, see the CH:LONN Stock Forecast page.

More about Lonza Group Ltd

Lonza Group is the world’s largest contract development and manufacturing organization focused on the healthcare sector. The Basel-based company partners with pharma and biotech firms across five continents to develop and manufacture therapies, generating CHF 6.5 billion in 2025 sales and CHF 2.1 billion in core EBITDA.

Average Trading Volume: 177,711

Technical Sentiment Signal: Hold

Current Market Cap: CHF33.13B

For a thorough assessment of LONN stock, go to TipRanks’ Stock Analysis page.